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Abstract
Cystic kidneys are common causes of end-stage renal disease, both in children and in adults. 
Autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic 
kidney disease (ARPKD) are cilia-related disorders and the two main forms of monogenic cystic 
kidney diseases. ADPKD is a common disease that mostly presents in adults, whereas ARPKD is 
a rarer and often more severe form of polycystic kidney disease (PKD) that usually presents 
perinatally or in early childhood. Cell biological and clinical research approaches have expanded 
our knowledge of the pathogenesis of ADPKD and ARPKD and revealed some mechanistic 
overlap between them. A reduced ‘dosage’ of PKD proteins is thought to disturb cell homeostasis 
and converging signalling pathways, such as Ca2+, cAMP, mechanistic target of rapamycin, WNT, 
vascular endothelial growth factor and Hippo signalling, and could explain the more severe clinical 
course in some patients with PKD. Genetic diagnosis might benefit families and improve the 
clinical management of patients, which might be enhanced even further with emerging therapeutic 
options. However, many important questions about the pathogenesis of PKD remain. In this 
Primer, we provide an overview of the current knowledge of PKD and its treatment.
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In patients with polycystic kidney diseases (PKDs), the kidneys contain multiple fluid-filled 
cysts, although other organs may also be affected (FIG. 1). Although PKD is inherited 
monogenically, it is phenotypically, genically and allelically heterogeneous. Autosomal 
dominant PKD (ADPKD) is the most common form of PKD and is generally an adult-onset, 
multisystem disorder that is characterized by gradually growing renal cysts that start to 
develop in utero and can originate from all areas of the kidneys, although cysts usually form 
in the distal regions of the nephron and the collecting duct. Progressive fibrocystic renal 
disease in ADPKD is often accompanied by hepatobiliary changes or other extrarenal 
abnormalities, such as intracranial arterial aneurysms1,2. Mutations in PKD1 or PKD2, 
which encode polycystin 1 (PC1) and PC2, respectively, are the most common cause of 
ADPKD. PC1 and PC2 form a heterodimeric complex through the interaction of the coiled-
coil motifs in the carboxy-terminal tails of each protein, which likely functions at primary 
cilia. PC2 is a cation channel that is a member of the transient receptor potential (TRP) 
family of ion channels, which are ubiquitously present across evolution and usually contain 
six membrane-spanning helices that are flanked by an intracellular amino terminus and 
carboxyl terminus (FIG. 2). By contrast, the roles of PC1 and the PC1–PC2 complex are 
only poorly understood. Autosomal recessive PKD (ARPKD) is rarer, and the clinical course 
is usually much more severe than with ADPKD. ARPKD typically manifests perinatally or 
in childhood, and patients often die perinatally or in infancy. Manifestations of the disease 
include hepatic fibrosis and greatly enlarged kidneys, and cysts typically affect the collecting 
ducts. ARPKD is primarily caused by mutations in polycystic kidney and hepatic disease 1 
(PKHD1), which encodes fibrocystin (also known as polyductin), a protein that localizes to 
the primary cilium and basal body.
Although single renal cysts are common and usually benign in adults, bilateral cystic 
kidneys require careful clinical assessment to identify the underlying genetic disorder, 
especially in children, owing to major implications for the patient and family. Both ADPKD 
and ARPKD often result in chronic kidney disease (CKD; a gradual loss of kidney function) 
and end-stage renal disease (ESRD; severe kidney disease that requires dialysis or kidney 
transplantation for patient survival), which are associated with substantial associated 
morbidity and mortality.
In the past decade, progress has been made in unravelling the aetiology of PKD. Studies 
have shown that the proteins encoded by genes associated with PKD colocalize in 
multimeric complexes at distinct subcellular sites in epithelial cells, and compelling 
evidence exists to suggest that primary cilia have a central pathogenic role in PKD3–5. Cell 
biological and clinical research approaches have further extended our understanding of the 
pathophysiology of PKD and are starting to help in the identification of rational personalized 
therapies.
In this Primer, we provide a general overview of the current knowledge of ADPKD and 
ARPKD, including the epidemiology, pathophysiology, prevention, prognosis and quality of 
life (QOL). Furthermore, we discuss the diagnostic approaches and the clinical management 
of PKD and its comorbidities in greater detail. Finally, we provide a brief outlook and 
discuss potential future therapeutic options.
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Epidemiology
ADPKD
ADPKD is the most common potentially lethal (that is, it results in renal failure and death in 
the absence of renal replacement therapy (RRT)) single-gene disorder and the most prevalent 
inherited progressive kidney disease2. The prevalence of ADPKD is reported to be between 
1 in 400 and 1 in 1,000 live births, mainly on the basis of two early landmark clinical 
studies, in Denmark6 and in Minnesota, USA7. On the basis of this prevalence, ADPKD is 
predicted to affect >10 million people worldwide in all ethnic groups and therefore 
constitutes a major public health burden.
To ascertain the exact prevalence of a hereditary disease, several factors must be considered8 
— the geographic and ethnic composition and the size of the population, the choice and 
mode of calculation of epidemiologic measurement, the screening policies and other 
characteristics of the health-care system, the disease definition and diagnostic criteria that 
are used, the sources of ascertainment and possible causes of under-ascertainment and the 
period of time during which events are counted (ascertainment period). Thus, variability in 
study design and ascertainment might partially explain the large differences in estimates of 
the prevalence of ADPKD that have been reported in some studies. For example, two 
clinical surveys in Europe (carried out in the United Kingdom9 and in France10), as well as a 
survey in the Seychelles11 measured the prevalence of symptomatic individuals and 
estimated the prevalence of asymptomatic individuals. The estimated prevalence of ADPKD 
was 1 in 2,459 in the UK study, 1 in 1,111 in the French study and 1 in 542 for the 
Seychelles. In the study of the Seychelles population, the researchers speculated that the 
high prevalence among white individuals might be due to a founder effect (that is, low 
genetic variation in a population because it was started by a small number of individuals).
Subsequent studies based on renal phenotypic features reported an ADPKD prevalence of 1 
in 2,700 to 1 in 4,000 in different populations in Europe and Japan12–15. A recent study on 
ADPKD prevalence in the European Union, which reviewed the epidemiology literature 
from 1980 to 2015 and was based mainly on the large Registry of the European Renal 
Association (ERA)–European Dialysis and Transplant Association (EDTA), estimated that 
the prevalence of ADPKD in 19 countries was 1 in 2,525 (REF.16); that is, fewer than 5 
cases in 10,000, which is the threshold for a rare disease in the European Union.Importantly, 
the prevalence rates estimated in all these studies were much lower than the ADPKD 
prevalence estimated from autopsy studies (≥1 in 500)6,7,17. These data suggest that marked 
under-ascertainment exists and that a considerable number of (probably only mildly or 
moderately) affected individuals remain undiagnosed18.
ADPKD is an important cause of ESRD, for which patients receive RRT, which includes 
haemodialysis, peritoneal dialysis, haemofiltration, haemodiafiltration and kidney 
transplantation. In a population-based registry in Germany, 32% of patients with ADPKD 
were receiving RRT14. ESRD occurs as a result of ADPKD in up to 75% of patients by 70 
years of age14,19–21. Age-adjusted sex ratios suggest that ADPKD is more progressive in 
men than in women (1.2–1.3 men to women) on the basis of rates of ESRD. A Canadian 
study reported that 25% of patients with ADPKD had ESRD by 47 years of age, 50% by 59 
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years of age and 75% by 70 years of age22. In a French study, 22% of patients with ADPKD 
had ESRD by 50 years of age, 42% by 58 years of age and 72% by 73 years of age23. A 
European study of >300,000 patients starting RRT between 1991 and 2010 reported that the 
age-adjusted and sex-adjusted incidence of RRT in patients with ADPKD increased slightly 
over the study period from 7.6 per million to 8.3 per million population24. The researchers in 
this study noted that the incidence of RRT had markedly increased over time in patients >70 
years of age, whereas no change was observed for the cohort of patients with ADPKD who 
were <50 years of age, suggesting that older patients are receiving RRT. In the UK Renal 
Registry, mortality in patients with ADPKD receiving RRT was 3.18–4.96 per 100 person-
years, which was lower than that of patients receiving RRT who had other renal diseases. 
The ADPKD group had a lower hazard for all-cause mortality than the other renal diseases 
group (adjusted HR 0.45, 95% CI 0.38–0.53)25. Cardiac diseases and infections were the 
leading causes of death in patients with ADPKD who received RRT24.
ARPKD
As ARPKD is much rarer than ADPKD, the available epidemiological data for ARPKD are 
not as extensive as those for ADPKD. The reported incidence of ARPKD in North, Central 
and South America is 1 in 26,500 live births, corresponding to a carrier frequency of ~1 in 
70 in non-isolated populations26. Isolated or inbred populations with many consanguineous 
marriages might have a much higher prevalence — an incidence of 1 in 8,000 births in 
Finland was reported27. Boys and girls seem to be equally affected by ARPKD. Of note, 
among children with PKD in paediatric nephrology departments, the total number of patients 
with early-onset ADPKD might be comparable to the number of children with ARPKD28. 
The overall prevalence of PKD in children is estimated to be ~1 in 10,000.
After delivery, the pulmonary status of neonatal infants usually dictates a requirement for 
early disease management of ARPKD. Mortality of 30–40% due to pulmonary hypoplasia 
has been reported for ARPKD29,30. However, for infants who survive the perinatal period, 
the long-term prognosis for patient survival is much better than generally perceived by many 
medical professionals. One-year and 10-year survival are ~85% and ~82%, 
respectively29–32.
Mechanisms/pathophysiology
The polycystin proteins are localized predominantly, although not exclusively, in the primary 
cilium, which is a hair-like structure that protrudes from the apical membrane of renal 
epithelial cells into the lumen of the nephron. The distribution of the polycystin proteins at 
different subcellular locations is required for them to orchestrate a network of signalling 
pathways that establish and maintain a differentiated renal epithelium33.
ADPKD
Genes and proteins.—Mutations in PKD1 (chromo-some 16p13.3) are responsible for 
almost 80% of cases of ADPKD, whereas ~15% of ADPKD cases are attributed to 
mutations in PKD2 (chromosome 4q22.1) and the remaining ~5–10% of ADPKD cases are 
genetically unresolved or are due to rare mutations in other loci18. These rare mutations that 
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result in an ADPKD-like phenotype occur in hepatocyte nuclear factor 1β (HNF1B; which 
is a transcription factor that upregulates the expression of multiple PKD-associated genes, 
including PKHD1 and PKD2), neutral α-glucosidase AB (GANAB; which is involved in 
protein folding)34,35 and DNAJB11 (which encodes a chaperone protein that is associated 
with binding-immunoglobulin protein (BiP; also known as HSPA5))36. In addition, ADPKD 
can result from mutations in genes that are primarily associated with autosomal dominant 
polycystic liver disease (ADPLD), including SEC63 (which encodes a protein that is 
required for protein translocation across the endoplasmic reticulum (ER) membrane) and 
PRKCSH (which encodes the regulatory β-subunit of glycosidase 2 that is involved in 
protein folding)37–39. Patients with mutations in GANAB can manifest with an ADPKD or 
ADPLD phenotype, and other possible ADPLD-causing genes include LRP5 (which 
encodes a WNT co-receptor), ALG8 (which encodes an α−1,3-glucosyltransferase) and 
SEC61B (which encodes the β-subunit of the SEC61 trans-locon)35,40. Carriers with a 
mutation in one PKHD1 allele may also sometimes manifest with a few liver or kidney 
cysts35,41. In addition, autosomal dominant tubulointer-stitial kidney disease (ADTKD) 
caused by mutations in uromodulin (UMOD), mucin 1 (MUC1), renin (REN) and SEC61A 
(which encodes the α-subunit of the SEC61 translocon) can also sometimes be mistaken for 
ADPKD, although ADTKD is usually associated with renal impairment without renal 
enlargement and with only a few cysts42–45. Mutations in COL4A1 (which encodes a 
collagen subunit), including those associated with hereditary angiopathy with nephropathy, 
aneurysms and muscle cramps (HANAC) syndrome46, can sometimes cause an ADPKD-like 
phenotype18. The X-linked ciliopathy caused by mutations in OFD1 (which encodes a 
centriole and centriolar satellite protein and is associated with oral-facial-digital syndrome 
type I) can also sometimes be confused with ADPKD, although additional facial and digital 
phenotypes are usually present. In summary, mutations in PKD1 and PKD2 are the main 
cause of ADPKD, but mutations that interfere with the biogenesis of PC1, reduce the 
expression of PKD1 or PKD2 or ciliopathy and other mutations can sometimes mimic 
ADPKD18. ADPKD can sometimes also be mimicked by the hereditary cancer syndromes 
tuberous sclerosis and von Hippel–Lindau syndrome in cases in which extrarenal features 
are either absent or mild47.
PC1 is a large, integral membrane protein of 4,303 amino acids with 11 transmembrane 
domains, an extensive extracellular domain containing multiple predicted motifs and a small, 
~200-amino acid intracellular carboxy-terminal tail that regulates multiple signalling 
cascades48 (FIG. 2). PC1 is cleaved at the G protein-coupled receptor proteolytic site to 
generate a large amino-terminal fragment that remains non-covalently tethered to the 
carboxy-terminal fragment at the plasma membrane49. This cleavage seems to regulate the 
biogenesis and trafficking of PC1 (REF.50). In addition, regulated cleavage of the 
intracellular C-terminal tail releases PC1 fragments into the cytoplasm, which translocate to 
the nucleus and interact with transcription activators, repressors and co-activators to 
modulate various signalling pathways51,52.
Although many of the functions of PC1 remain unclear, the C-terminal tail of PC1 is known 
to mediate the interaction of PC1 with PC2 (REF.53), which is involved in the regulation of 
ion transport and indirectly affects Ca2+ signalling. The cryo-electron microscopy structure 
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of PC2 establishes it as a homotetrameric ion channel, although it is possible that PC2 
heteromultimerizes with other TRP channel subunits or with PC1 (REFS54,55).
Patients with ADPKD usually carry a germline mutation in one allele of either PKD1 or 
PKD2 (see Diagnosis section, below), although at least one second event, such as somatic 
inactivation of the remaining wild-type PKD1 or PKD2 allele or loss of heterozygosity, is 
required to initiate cyst formation56–58. In addition, variants in other genes linked to PKD59 
or unidentified modifying genes, as well as environmental factors such as acute kidney 
injury, can modulate cyst formation and disease progression60,61. The likelihood of cyst 
formation substantially increases when the level of functional PC1 or PC2 drops below a 
critical threshold56–58,62,63; accordingly, the amount of functional PC1 or PC2 and, thereby, 
the type of mutation (for example, inactivating mutations or mutations that reduce the 
function of the gene product (hypomorphic mutations)) affect the likelihood of cyst 
formation and the disease progression62–64 (FIG. 3). In mice, disruption of Pkd1 in a small 
number (10%) of cells leads to an ~6-month dormant period in which there is no renal 
tubular dilatation, followed by a period with rapid cyst formation, suggesting that additional 
triggers are required to initiate cyst formation60,65.
Determinants of disease severity.—The renal phenotype in patients with ADPKD 
ranges from patients in old age without renal failure to rare cases of enlarged kidneys that 
are detected in utero18. The identity of the gene that is mutated in patients with ADPKD 
explains part of this phenotypic variability, so that patients with a mutation in PKD1 have 
earlier-onset ESRD, lower glomerular filtration rate (GFR) and larger kidney volumes than 
patients with a mutation in PKD2 (REFS64,66). Sex is increasingly recognized as important 
to the outcome of renal disease in patients with ADPKD — in general, renal disease is 
substantially more severe in men than in women66,67. However, >80% of patients with 
ADPKD and severe polycystic liver disease (PLD) are female, suggesting that hormonal 
differences might influence disease severity68. The role of PKD1 allelic effects is becoming 
clearer, as a considerable proportion of in-frame PKD1 mutations are incompletely penetrant 
(hypomorphic) and result in ESRD later in life, lower GFR and smaller kidneys than with 
more penetrant alleles64,66. However, genic or allelic effects do not seem to be important for 
the development of severe PLD in patients with ADPKD68.
Mutational inactivation of both alleles of PKD1 or PKD2 is thought to cause embryonic 
lethality in humans (as in mice); however, patients with biallelic mutations who are 
homozygous or compound heterozygous, with at least one weak PKD1 or PKD2 
hypomorphic allele (that is, with a reduced level of activity or expression), do survive63. 
Biallelic mutations cause rare severe cases of onset of ADPKD in utero59,69–72. A mouse 
model mimicking the hypomorphic PKD1R3277C allele shows the association of the dosage 
of functional PC1 to disease severity63. Digenic patients with ADPKD (that is, those with 
mutations in both PKD1 and PKD2) have more severe disease than monogenic family 
members, but digenic mutations are not lethal in humans73. The combination of an ADPKD 
allele with an allele of another cystogene, such as HNF1B, may also exacerbate the renal 
disease phenotype59.
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At least 10–15% of families with ADPKD have no family history of the disease, suggesting 
that de novo mutations occur at a considerable rate, and intrafamilial variability in this case 
can be explained by mosaicism, in which the proportion of cells that carry the mutation and 
those that contain the wild-type allele can differ substantially74,75. Mosaicism can be more 
reliably detected by next-generation sequencing (NGS)-based approaches than by 
conventional sequencing owing mainly to the superior sequencing depth in NGS47.
Finally, studies of twins and those that analysed inter-familial and intrafamilial variability in 
ADPKD severity suggest that other genetic factors contribute substantially to the variability 
in the severity of renal disease66,76–78, although, to date, the identity of these other genetic 
factors is unknown79.
Arterial hypertension.—Early in the course of ADPKD when renal function is still 
normal, most patients already develop arterial hypertension that contributes considerably to 
the increased cardiovascular morbidity and mortality observed in patients with ADPKD. 
Although various pathogenic mechanisms are known and activation of the renin–
angiotensin–aldosterone system (RAAS; a hormone system that regulates blood pressure 
and fluid balance) is clearly the most prominent, other mechanisms have also been 
described, including increased activity of the sympathetic nervous system and disturbances 
in the fine-tuning of vascular tone through the action of endothelin, nitric oxide (NO) and 
intracellular calcium (reviewed elsewhere33).
Cyst formation.—The cysts in patients with ADPKD are fluid-filled focal outgrowths 
from the renal epithelium, which arise in a minority (~1%) of nephrons and eventually 
detach when the amount of functional PC1 or PC2 drops below a critical threshold level. 
The polycystin proteins localize to the apical and basolateral plasma membrane, adherens 
junctions, desmosomes, focal adhesions and the primary cilium and are also secreted in 
microvesicles80. In addition, PC2 is localized to the ER and mediates Ca2+ release from this 
organelle. The polycystin proteins form multimeric protein complexes that modulate several 
signalling pathways, such as Ca2+, cAMP, mechanistic target of rapamycin (mTOR), WNT, 
vascular endothelial growth factor (VEGF) and Hippo signalling. Consequently, numerous 
cellular changes have been observed in cyst-lining cells, including alterations in apical–basal 
polarity, planar cell polarity (PCP), increased extracellular matrix production and cellular 
metabolism, involving essential cellular functions such as fluid transport, proliferation, 
apoptosis, cell adhesion and differentiation81–85 (FIG. 4).
However, as PKD progresses, the molecular alterations in the kidneys are increasingly the 
consequence of secondary events that disrupt the network of signalling pathways. Reduced 
Ca2+ influx, increased cAMP levels and aberrant RAS–RAF–ERK activation in renal 
epithelial cells are important mediators of cyst growth. which is further sustained by 
increased growth factor signalling86,87. For example, increased levels of epidermal growth 
factor receptor (EGFR) and its mislocalization to the apical surface of cystic epithelial cells, 
together with the presence of the ligands EGF and transforming growth factor-α (TGFα) in 
cyst fluid, probably promote tubular epithelial cell proliferation88,89. Other mechanisms that 
might be involved in cyst growth include altered signalling through G proteins, mTOR, 
phosphoinositide 3-kinase (PI3K)–AKT, AMP-activated protein kinase (AMPK), Janus 
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kinase 2 (JAK2)–signal transducer and activator of transcription 1 (STAT1; or STAT3 or 
STAT6), nuclear factor of activated T cells (NFAT) and nuclear factor-κB (NF-κB)90–97. In 
addition, cyst expansion is accompanied by changes in cellular metabolism — increased 
glucose consumption that is indicative of ATP synthesis through aerobic glycolysis, and 
impaired fatty acid oxidation, seem to be additional features of ADPKD83,98–102. Cysts can 
induce stress (presumably mechanical) on neighbouring nephrons, resulting in apoptosis of 
renal epithelial cells and thereby locally increasing the likelihood of cyst formation65.
The polycystin complex localized in the primary cilium was initially thought to transduce 
extracellular fluid flow-generated shear stress into a cellular Ca2+ signal86, but subsequent 
studies suggested that although polycystin proteins induce local changes in ciliary calcium 
concentration through their channel function, global cytoplasmic calcium levels are not 
substantially altered87. Intriguingly, the engineered loss of cilia ameliorates the cystic 
phenotype in Pkd1-mutant mice or Pkd2-mutant mice, suggesting that, in healthy kidneys, 
the polycystin proteins inhibit a cilia-regulated cystogenic signalling pathway that controls 
renal epithelial cell proliferation103.
However, the function of the polycystin proteins at other subcellular locations should not be 
underestimated. Simultaneous ablation of Pkd1 and Itgb1 (which encodes β1 integrin) in 
mice resulted in inhibition of Pkd1 ablation-dependent cystogenesis and suppression of 
fibrosis, suggesting that PC1 represses signalling that regulates the crosstalk between the 
extracellular matrix and integrins104. Although a direct association between PC1 and β1 
integrin has not been detected, PC1 interacts with the cytoskeletal adaptor proteins vinculin 
and paxillin, which are essential for integrin signalling through focal adhesion complex 
proteins, such as focal adhesion kinase (FAK) and SRC105. The accumulation of the 
extracellular matrix and the recruitment of inflammatory cells can already be observed at 
early stages of the disease. In particular, M1 and M2 macrophages are important contributors 
to disease progression. Macrophages and interstitial fibroblasts also produce cytokines, and 
abnormal cytokine-mediated crosstalk between renal epithelial cells and inflammatory cells 
results in a positive feedback loop of increasing fibrosis (FIG. 5).
In addition to altered cell–matrix interactions, the cell–cell junctions in cyst-lining epithelia 
are also abnormal106. The abnormal composition and localization of adherens junctions and 
desmosomes in ADPKD suggest that the polycystin proteins regulate the dynamics of cell–
cell adhesions to reduce their mechanical strength and allow cytoskeletal remodelling in 
ADPKD106,107.
As a consequence, the integrity of apical–basal polarity and PCP is compromised in cystic 
epithelial cells108. However, although disruption of PCP signalling results in inaccurate 
control of tubule diameter, it is not cystogenic109. These data suggest that PKD mutations do 
not disrupt PCP signalling but instead act independently of and in parallel with PCP 
signalling to affect oriented epithelial cell division107.
Overall, cystic epithelia often have a partially de-differentiated phenotype, suggesting that 
mutations in the PKD genes result in cells reverting to a developmental pattern of gene 
expression. Although the molecular mechanisms of polycystin regulation of various 
Bergmann et al. Page 8
Nat Rev Dis Primers. Author manuscript; available in PMC 2019 June 25.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
signalling pathways at different subcellular locations are not fully understood, this network 
of signalling pathways seems to be crucial for establishing and maintaining a differentiated 
renal epithelium60.
Histopathological changes.—Epithelial cell proliferation, abnormal fluid secretion and 
excessive extracellular matrix deposition are the major characteristics of cystic epithelial 
cells. These changes are accompanied by alterations in the pericystic blood and lymphatic 
microvas-culature110–112. Most cysts detach from the tubules from which they form and fill 
with fluid by transepithelial secretion113. Cyst enlargement also compresses the surrounding 
nephrons, interstitium and vasculature. The obstructed nephrons eventually form atubular 
glomeruli and apoptotic proximal tubules114.
These events are accompanied by the production of chemokines, cytokines and growth 
factors by epithelial cells, interstitial fibroblasts and inflammatory cells, such as 
macrophages115,116. Abnormal cytokine-mediated crosstalk between epithelial and 
inflammatory cells promotes more inflammation and fibrosis, new cyst formation and 
disease progression, which result in massively fibrotic kidneys at end-stage disease117 (FIG. 
5). Increased inflammation is probably an early event in disease progression, and the 
selective depletion of macrophages in the kidneys of a Pkd1 mouse model resulted in 
considerable amelioration of the cystic phenotype and improvement in renal function118. 
Macrophage migration inhibitory factor (MIF) is an important pro-inflammatory cytokine in 
PKD, as deletion of Mif delayed cyst growth and improved renal function in Pkd1 -knockout 
mice119.
Extrarenal pathology.—ADPKD is a systemic disease and, in addition to the renal 
pathology, patients develop liver cysts and cardiovascular abnormalities. PLD is 
characterized by the presence of multiple cysts scattered throughout the liver parenchyma, 
which form owing to overgrowth of the biliary epithelium. The severity of PLD can range 
from a few hepatic cysts to a massively enlarged cystic liver. As in renal epithelia, a 
substantial reduction or complete loss of function of the polycystin proteins underlies liver 
cyst formation120. PLD can also occur as a distinct disease, without the involvement of renal 
cysts, as ADPLD. Although ADPLD is caused by mutations in a set of genes that are 
distinct from those involved in ADPKD, studies in mice suggest that mutations in these PLD 
genes affect the dosage of PC1, which seems to be the rate-limiting determinant of liver cyst 
formation121.
Patients with ADPKD also have cardiovascular abnormalities, including hypertension, left 
ventricular hypertrophy, aortic root dilatation, arterial aneurysms, heart valve abnormalities 
and intracranial aneurysms (ICAs) (reviewed elsewhere122). Numerous lines of evidence 
suggest that the vascular and cardiovascular defects are directly related to reduced 
expression of the polycystin proteins (haploinsufficiency) in the endothelial cells and 
vascular smooth muscle cells (VSMCs) of most blood vessels, including the aorta and 
cerebral arteries110,114. Indeed, the risk of cerebral aneurysms is higher in families with a 
positive family history of ADPKD than those without, probably because of modifying 
genes123. The functions of PC1 and PC2 in the vasculature indicate that they have a crucial 
role in mechanosensation. In endothelial cells, the proteins are involved in fluid-shear stress 
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sensing, thereby regulating calcium signalling and NO release124. NO released by 
endothelial cells affects vasodilatation in response to increased blood flow. In VSMCs, the 
polycystins regulate pressure sensing by modulating the activity of the stretch-activated 
cation channels and myogenic contraction125. A loss of myogenic tone may contribute to 
aneurysm formation owing to an increase in arterial wall stress125. Finally, studies of 
haploinsufficient and hypomorphic models of ADPKD have shown that vascular changes are 
associated with a reduction of the levels of polycystin proteins126–128.
The PKD genes are expressed in a wide range of tissues beyond the kidney, and their 
expression is developmentally regulated in most of these tissues. Accordingly, other 
extrarenal manifestations can occur, including cysts in the pancreas, seminal vesicles and the 
arachnoid membrane, in patients with ADPKD115. Although patients with a single or those 
with more than one mutant PKD allele usually have relatively restricted disease phenotypes 
(that is, cysts or manifestations in only a few organs), complete knockout of Pkd1 or Pkd2 in 
mice results in embryonic lethality that is associated with a wide range of abnormalities, 
including: severely cystic pancreas, kidneys and liver; cardiac abnormalities; vascular 
defects (such as oedema and vascular leakage); craniofacial defects; bone defects; and, 
rarely, polyhydramnios (excess amniotic fluid)129–133. Tissue-specific Pkd1 or Pkd2 
disruption results in hydrocephalus and lymphatic abnormalities in mice112,134. The species-
specific differences in ADPKD phenotypic severity suggest that the levels of polycystin 
proteins in most human tissues do not drop below a critical threshold or that when this 
happens, the affected cells might undergo apoptosis.
Experimental models.—To gain insight into the disease mechanisms and pathogenesis of 
ADPKD, various mouse models have been genetically engineered33, including inducible, 
conditional knockout mice and mouse models with hypomorphic or hypermutable alleles of 
Pkd1 or Pkd2, which are extremely useful as ablation of Pkd1 or Pkd2 results in embryonic 
lethality and heterozygous mice develop only very mild disease, even in old age62,63,135–139. 
These models are characterized by the age of disease onset, the progressiveness of the 
disease, the nephron segment that is affected, the number of affected nephrons, whether cyst 
formation is synchronized or unsynchronized and the extent of renal fibrosis and 
inflammation. These models enable step-by-step analysis of the pathogenesis of ADPKD 
and have provided valuable mechanistic insights into the early stages and the later, 
progressive stages of the disease. Findings in tissues from mouse models of early disease are 
complementary to those in renal tissues from patients with ADPKD, as the kidneys are 
usually removed from patients with the progressive stages of ADPKD or ESRD. Examples 
of the value of animal models include their role in highlighting the difference in the severity 
of renal disease observed when Pkd1 is inactivated during renal development compared with 
after the kidneys have formed137,138. In addition, renal damage was shown to increase the 
severity of PKD in haploinsufficient mice60,140. Finally, hypomorphic models have shown 
that polycystic kidneys can develop when polycystin function is reduced but not 
eliminated62,63.
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ARPKD
Genes and proteins.—The polycystic kidneys and congenital hepatic fibrosis (CHF) 
observed in ARPKD suggest that terminal differentiation of the renal collecting ducts and 
intrahepatic biliary ducts is disordered in this disease. Histological analysis has revealed that 
the changes in the liver that are invariably present from early embryonic development in 
patients with ARPKD are characterized by defective remodelling of the ductal plate with 
CHF and biliary duct ectasia, defined as ductal plate malformation (DPM; FIG. 6), which 
also occurs frequently in other cilia-related disorders (ciliopathies), such as 
nephronophthisis, Joubert syndrome and Bardet–Biedl syndrome, some ofwhich may have 
an ARPKD-like phenotype1,141. Different types of variants in PKHD1 (6p12.3–12.2), such 
as missense and truncating mutations, are responsible for most cases of ARPKD (discussed 
further in the Diagnosis section).
The mRNA of PKHD1 is alternatively spliced to produce multiple transcripts142,143. The 
longest transcript encodes a 4,074-residue protein comprising a single transmembrane 
domain, an extensive extracellular N-terminal domain and a short C-terminal cytoplasmic 
tail (FIG. 2). Fibrocystin localizes to the primary cilium and to other cellular 
compartments142,144,145 and is targeted to the ciliary membrane by a specific motif in its C 
terminus146. In addition, similar to Notch, fibrocystin is proteolytically cleaved to release the 
cytoplasmic tail, which translocates to the nucleus and presumably regulates downstream 
target genes. Although this remains to be conclusively established, it is possible that the C-
terminal tail of fibrocystin regulates the expression of genes that encode proteins that drive 
cyst formation147,148.
In addition, mutations in the gene encoding the ciliary transition zone protein DAZ-
interacting protein 1-like protein (DZIP1L) have been described in some pedigrees in which 
the affected children had clinically moderate ARPKD and no evidence of mutations in 
PKHD1 (REF.132; C.B., unpublished data). DZIP1L is a 767-residue soluble zinc-finger 
protein that, similar to PC1, PC2 and fibrocystin, localizes to centrioles and the distal end of 
basal bodies. DZIP1L interacts with septin 2 (SEPT2; in the septin ring), a protein that is 
implicated in the maintenance of the periciliary diffusion barrier at the ciliary transition 
zone. Consistent with a defect in the diffusion barrier, the localization of PC1 and PC2 to the 
ciliary membrane is compromised in DZIP1L-mutant cells132. Diseases with symptoms 
similar to those in ADPKD and ARPKD might also be caused by mutations in other genes 
(reviewed in detail elsewhere1). Of note, mutations in PKD1 and PKD2 can also be inherited 
in a recessive manner (homozygous or compound heterozygous) with at least one weak 
PKD1 or PKD2 hypomorphic allele; these patients can present with an ARPKD-like 
phenotype141.
Finally, PKD (mimicking ARPKD or ADPKD) with hyperinsulinie hypoglycaemia was 
described in 11 pedigrees and was linked to biallelic mutations (including a specific 
promoter mutation) in phosphomannomutase 2 (PMM2)149. PMM2 is a key enzyme in N-
linked glycosylation, and recessive mutations in PMM2 are usually associated with 
congenital disorder of glycosylation type 1a, which has a severe, pleiotropic phenotype.
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Determinants of disease severity.—Efforts to assess geno-type–phenotype correlations 
for PKHD1-linked ARPKD have been hampered by multiple allelism (that is, the presence 
of many different mutations in the same gene) and the high incidence of different compound 
heterozygotes (that is, the presence of two different mutant alleles at a single locus). 
However, genotype–phenotype correlations have been made for the type of mutation instead 
of the site of individual mutations150. Allelic effects are known; for example, patients with 
two truncating mutations in PKHD1 often have severe disease that is usually lethal (although 
a few exceptions have been described) and surviving patients typically have at least one 
inframe mutation30,150. These data indicate that many missense mutations do not completely 
abrogate PKHD1 function. Notwithstanding, some missense mutations in PKHD1 result in 
disease that is as severe as that resulting from truncating mutations. No substantial clinical 
differences have been observed between patients with two missense mutations and patients 
with a truncating mutation in trans; thus, the milder mutation seems to define the disease 
severity. Substantial intrafamilial variability among a considerable number of siblings 
indicates that other genetic and environmental factors also influence the disease 
phenotype32.
The clinical course in patients and siblings with DZIP1L mutations described above was 
invariably moderate. Although the clinical manifestations in all of these patients were 
initially detected prenatally or during early childhood, none of the patients died perinatally. 
To date, the data are consistent with the idea that the type or location of the mutation in 
DZIP1L does not determine the severity of the clinical course. Patients who have missense 
mutations in both parental DZIP1L alleles have a phenotype comparable to that of patients 
who have two truncating DZIP1L alleles. Although genetic screening of a large number of 
patients who died perinatally has not been carried out, in view of homozygous truncating 
mutations in two patients132, we hypothesize that it is unlikely that DZIP1L mutations play a 
major role in this cohort of mostly severely affected patients. This hypothesis is consistent 
with the birth of homozygous Dzip1l-mutant outbred mice at the expected Mendelian 
frequencies132. However, the identification of additional families with DZIP1L mutations is 
required to draw firm conclusions.
Cyst formation.—ARPKD cysts arise predominantly from the distal tubules and 
collecting ducts, but the detailed mechanisms of cyst formation are only poorly understood. 
Fibrocystin is expressed postnatally predominantly in the kidneys, liver and pancreas, and as 
mentioned earlier, fibrocystin localizes to the apical membranes as well as to primary cilia, 
especially at the basal body and the mitotic spindle in renal tubular cells and biliary 
epithelial cells145,151,152. DZIP1L is widely expressed and is localized primarily to 
centrioles and the distal end of basal bodies. Although little is known about the molecular 
functions of fibrocystin and DZIP1L, fibrocystin has been shown to interact with PC2 within 
the PC1–PC2 complex153. In addition, as in ADPKD, the cAMP, MYC and mTOR 
signalling pathways are activated in ARPKD154 and thus represent potential targets for 
directed therapeutic intervention.
Experimental models of ARPKD.—To date, multiple Pkhd1-based models of ARPKD 
have been described, which were primarily generated by gene-targeting methods in mice. 
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Although an ARPKD-like liver phenotype is invariably present in all of these mouse models, 
a renal phenotype is often absent, and when present, it is a mild, slowly progressive lesion 
that typically involves the proximal tubules rather than the collecting ducts. Interestingly, 
several models also have a severe pancreatic ductal phenotype, whereas clinically significant 
pancreatic disease in patients with ARPKD is quite rare. The mechanism that underlies the 
mild renal phenotype in these animal models remains unclear. However, as genetic 
background seems to have a major effect on renal pathology, genetic modifiers likely 
modulate renal disease155. In the PCK rat, which arose owing to a spontaneous mutation in 
Pkhd1 (REF.144), the hepatic phenotype is very similar to that in ARPKD, whereas the 
slowly progressive renal cystic disease in this model more closely resembles the renal cystic 
lesions in ADPKD than in ARPKD156. Introgression of the Pkhd1 mutation in the PCK rat 
into a different background ameliorated the renal but not the hepatic phenotype, again 
suggesting that genetic factors modulate the severity of the renal cystic phenotype157.
Consistent with the extensive phenotypic variability observed in experimental models of 
ARPKD, Dzip1lwpy/wpy mice (which were identified in an N-ethyl-N-nitrosourea-induced 
mutagenesis screen and contain a nonsense mutation in Dzip1l) display a number of 
embryonic morphological defects, including limb and craniofacial defects, in addition to 
cystic kidney disease and hepatobiliary DPM132. The amelioration of the craniofacial 
phenotypes by crossing Dzip1lwpy/wpy mice with an outbred strain suggests that at least 
some of the phenotypic differences with the human ARPKD may be due to genetic 
background effects. Tissue-specific changes in the expression of genes involved in 
Hedgehog signalling, such as gene expression changes in the limb that are consistent with 
polydactyly, were detected in Dzip1lwpy/wpy embryos132.
Diagnosis, screening and prevention
ADPKD
Diagnosis.—ADPKD is a progressive disease in which renal cyst development begins in 
utero, although cyst initiation and enlargement continue throughout the patient’s life158. 
Cyst enlargement results in an exponential increase in total kidney volume (TKV; expressed 
relative to height (htTKV)) and often results in ESRD159. Clinical symptoms, including 
early-onset hypertension, abdominal fullness and pain, haematuria and urinary tract 
infections (UTIs), are usually first observed decades (sometimes even in childhood) before 
the onset of renal insufficiency2 (the numerous manifestations of the disease are described in 
TABLE 1).
Presymptomatic diagnosis can usually be made in at-risk family members (such as children 
or siblings of affected individuals) by abdominal imaging, and the presence of multiple 
bilateral cysts identifies affected individuals. Ultrasonography is the most common and least 
expensive imaging method, but CT or MRI can provide more quantitative data (that is, 
htTKV) of prognostic value (FIG. 7). As cyst development in ADPKD is related to age, and 
even genetically unaffected individuals can develop a few simple cysts as they age160, 
criteria have been developed to define whether at-risk individuals are affected on the basis of 
number of cysts by age (TABLE 2).
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The corresponding number of MRI-detected cysts that are considered to be diagnostic has 
been defined as more than ten in those aged 16–40 years; fewer than ten cysts does not 
classify as PKD161. In patients without an established family history, the detection of more 
than ten cysts per kidney by ultrasonography is usually considered diagnostic162, but genetic 
diagnostic testing would be valuable.
Imaging provides a less certain diagnosis in young adults owing to the late and only mild 
disease manifestation in some patients; therefore, in these cases and others, genetic analysis 
may be helpful to obtain a definite diagnosis (BOX 1).
Obtaining a genetic diagnosis of ADPKD is complex because of historical segmental 
intrachromosomal duplication of three-quarters of the PKD1 gene (at the 5′ end), which 
produced six pseudogenes that have up to 99% sequence homology with PKD1. 
Consequently, specialized screening of PKD1 is required because mutations are not always 
detected by whole-exome sequencing (WES). Traditionally, genetic diagnostic analysis has 
involved using PKD1 -specific long-range PCR fragments that exploit the rare sequence 
differences between PKD1 and the pseudogenes, followed by Sanger sequencing or NGS of 
the long-range products to identify mutations163–165. However, newer sophisticated NGS 
methods that use specific capture workflows and in silico analyses166,167 or whole-genome 
sequencing (WGS)168 have been reported, and capture-panel-based approaches are now 
favoured for genetic diagnosis of ADPKD.
Furthermore, interpretation of the results of genetic diagnostic analysis is complicated not 
only by the PKD1 pseudogenes but also by the high level of allelic heterogeneity in PKD1 
and PKD2, in which >1,900 different mutations have been described, and no single mutation 
accounts for >2% of the total patient population (ADPKD Mutation Database). A substantial 
proportion of PKD1 mutations are in-frame (~30%), and because this gene has >300 
described neutral non-synonymous variants, determining whether a missense variant is 
pathogenic is not always straightforward. Inquiry of the ADPKD Mutation Database and the 
use of scoring algorithms together with contextual information from population databases 
(for example, the Genome Aggregation Database (gnomAD) and family studies can help 
determine the pathogenicity of these variants66,163,169,170. In ~7% of ADPKD families, no 
mutation is detected64,66,163,164; some of these families probably have mutations at the 
known PKD loci that were not detected (for example, deep intronic or regulatory mutations), 
including mosaic cases that are probably more common in patients with de novo mutations 
than is currently reported75,171,172. In addition, further genetic heterogeneity is likely, as 
mutations in GANAB were identified as a cause of mild ADPKD, which represents ~0.3% 
of all cases34, and DNAJB11 mutations cause a hybrid of ADPKD and ADTKD36. 
Phenocopies of the ADPKD phenotype can also be due to mutations in HNF1B and in other 
genes, such as those associated with ADPLD that result in an ADPKD-like 
phenotype173,174. Parental renal ultrasonography should be carried out for family members 
of children who have cystic kidney disease of unknown origin. However, the family history 
is often unremarkable because of de novo mutations and combinations of incompletely 
penetrant (hypomorphic) alleles.
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Asymptomatic at-risk individuals <18 years of age are usually not screened but decide 
whether and when to be tested as an adult31,175. The rationale for this recommendation is 
based on the current lack of disease-specific treatments for those individuals <18 years of 
age and, in the USA at least, problems can occur with obtaining medical insurance and with 
workplace issues, despite antidiscrimination legislation. When necessary, monitoring and 
treatment of arterial hypertension and UTIs in at-risk children are recommended. However, 
the recommended age of testing may change if therapies become available for those <18 
years of age after the completion of clinical trials in children and teenagers. Treatment of 
young individuals (even children) before irreparable kidney damage has occurred might be 
particularly effective. Increasing evidence exists that important predictors of future 
cardiovascular events and mortality (such as left ventricular hypertrophy, biventricular 
diastolic dysfunction, endothelial dysfunction, increased carotid intima–media thickness and 
impaired coronary flow velocity reserve) are evident in children and young individuals with 
normotensive blood pressure and normal kidney function very early in the disease course 
and that patients might benefit from an early diagnosis75,176,177.
Prognosis.—Identifying patients with rapidly progressing disease would facilitate 
selection for clinical trials and treatment. Separating patients into classes on the basis of age-
related htTKV (the Mayo Classification), and exclusion of atypical patients, have been 
proposed as an efficient means to identify patients with the most rapidly progressing 
disease178. Combining genic and allelic information with clinical indications (onset of 
hypertension at <35 years of age and/or first urological event at <35 years of age) has also 
enabled identification of a population with rapidly progressing disease (the PROPKD score, 
a prognostic algorithm to predict renal outcomes in patients with ADPKD on the basis of 
genetic and clinical data)67,179. European recommendations have highlighted a demonstrated 
rapid decline in GFR in younger patients and/or a recorded rapid increase in htTKV as a 
means to identify patients with rapidly progressing disease who are suitable for treatment179.
Prenatal screening.—As ADPKD is an adult-onset disease, prenatal screening is not 
commonly carried out, but there is increasing interest in this procedure, especially from 
families with experience of early-onset renal disease or early ICAs. Of note, affected 
families with children with early-onset ADPKD have a high risk of subsequent children also 
having early and severe ADPKD, and this information should be shared with affected 
families1. Preimplantation genetic diagnosis is available for ADPKD, including analysis of 
the duplicated PKD1 locus, and may be more commonly sought in the future44.
ARPKD
Diagnosis.—ARPKD is phenotypically highly variable: at its most severe, ARPKD 
presents in utero, at birth or in infancy and is characterized by bilaterally enlarged, 
echogenic kidneys with poor corticomedullary differentiation, retained reniform contour and 
multiple tiny cysts that are confined to the distal tubules and collecting ducts (FIG. 8); 
presentation in older children, teenagers or young adults includes manifestations of portal 
hypertension or cholangitis; and moderate presentation is seen rarely in older adults with 
complications of liver disease or with renal manifestations, such as proteinuria, 
nephrolithiasis and renal insufficiency180–183. Those patients who survive the perinatal 
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period then transition from paediatric to adult care with internal medicine specialists184. 
With the advent of NGS-based molecular diagnostic testing, it has become evident that 
mutations in various other genes, such as HNF1B and those associated with ADPKD and 
many ciliopathies, can produce a phenotype that mimics the symptoms in ARPKD141.
Potter sequence consists of pulmonary hypoplasia, characteristic facies and spine and limb 
abnormalities and can be present in severe neonatal cases, with death from respiratory 
distress occurring in at least 20% of cases26,30,32. Surviving infants can experience 
childhood ESRD as well as liver complications owing to CHF that worsens with age. 
Patients who present with ARPKD later in childhood or as adults are more likely to have 
complications of portal hypertension, whereas renal enlargement is less evident than in 
patients who present earlier32,181. With advancing clinical course, the kidney structure might 
increasingly resemble the symptoms observed in ADPKD, including renal cysts that vary 
considerably in size and appearance, often accompanied by some interstitial fibrosis185. 
However, in contrast to the persistent renal enlargement that occurs in ADPKD, in ARPKD 
the kidneys decrease in size as the amount of fibrosis increases.
A diagnosis of ARPKD is likely to be based on clinical imaging in severe neonatal or 
infantile cases on the basis of enlarged echogenic kidneys, a negative family history of PKD 
and a lack of additional features (such as central nervous system abnormalities, eye defects 
and/or polydactyly) that may suggest a syndromic ciliopathy1. However, molecular 
diagnostic analysis is the gold standard for diagnosing this disorder, and a number of pheno-
copying disorders or syndromes must be considered1. Genetic testing can be particularly 
important in the diagnostic evaluation of patients with early-onset bilateral renal cystic 
disease. In older patients, CHF with or even without renal cysts may indicate ARPKD and 
molecular diagnostic analysis may help confirm the diagnosis47.
The large size of the PKHD1 gene (12,222 bp coding sequence, 67 exons and spans ~470 
kb)142,144 and a high level of allelic heterogeneity (~60% of mutations are inframe and 40% 
of mutations are truncating150,186) complicate the molecular diagnosis of ARPKD. Some 
mutations in PKHD1 are more common than others and some are enriched in specific 
populations; for example, T36M is the most common mutation and accounts for ~10–15% of 
mutant alleles in European populations150,186,187. Analysis of DZIP1L is much easier than 
for PKHD1, as it has a 2,301 bp coding sequence, 16 exons and spans only ~53 kb. 
Mutations in DZIP1L are a considerably rarer cause of ARPKD than PKHD1 mutations132, 
perhaps in part owing to the larger size of PKHD1 compared with DZIP1L. Furthermore, 
limited data suggest that the genomic region encoding the N terminus of DZIP1L may be 
more susceptible to mutations, which is supported by in silico data that predict that 
pathogenicity scores decay towards the C terminus132.
In practice, and reflecting the phenotypic overlap of ARPKD with syndromic ciliopathies as 
well as other forms of PKD, including ADPKD, screening a panel of genes is now often 
considered to be the gold standard for diagnostics147,167. Advances in NGS now enable 
simultaneous analysis of a large group of genes in a single test at fairly low cost. We expect 
that single-gene testing will soon be the exception rather than the rule, especially for 
genetically heterogeneous disorders with a broad phenotypic spectrum such as PKD. 
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However, at present, targeted NGS panel testing might be the most efficient diagnostic 
approach. Whichever primary strategy is chosen for PKD diagnosis, it should be able to 
detect copy number variations such as heterozygous deletions (for example, in HNF1B) and 
to cover complex genomic regions, such as PKD1.
Prognosis.—In accordance with autosomal recessive inheritance, the recurrence risk for 
subsequent pregnancies of parents of an affected child with ARPKD is 25%. Males and 
females are equally affected30. By definition, heterozygous carriers should not show any 
clinical disease manifestation, but data suggest that individuals who are heterozygous for 
PKHD1 mutations have an increased risk of PLD and mild PKD35,41. Other relatives (such 
as healthy siblings) or the affected patients themselves may seek genetic counselling and can 
usually be reassured of a very low risk (<1%) for ARPKD for their own offspring if their 
partner is not affected by ARPKD and has no family history of PKD.
Prenatal screening.—Many parents of children with ARPKD seek early and reliable 
prenatal diagnosis of subsequent children to guide future family planning. Frequently, 
patients with ARPKD are diagnosed by ultrasonography only late in pregnancy or at birth. 
However, fetal sonography at the time when pregnancies are usually terminated may fail to 
detect enlargement and increased echogenicity of the kidneys or oligohydramnios 
(deficiency of amniotic fluid) secondary to poor fetal urine output. Thus, an early and 
reliable prenatal diagnosis of ARPKD in at-risk families is feasible only by molecular 
genetic analysis. Prenatal diagnosis should be offered only to families for which there is an 
unequivocal diagnosis in an affected family member. However, prenatal molecular genetic 
analysis is usually done using chorionic villus sampling, which is an invasive procedure that 
is carried out quite late in pregnancy (no earlier than week 10–12 of gestation). Interested 
families should also be informed about the possibility of preimplantation genetic diagnosis 
with in vitro fertilization at some diagnostic centres. Preimplantation genetic diagnosis 
always requires a high degree of coordination between different medical specialists and a 
health assessment in advance. In the future, it might be possible to conduct non-invasive 
prenatal testing of the fetal genotype by screening a maternal blood sample188.
When considering prenatal testing, medical and ethical implications require a careful review 
by attending physicians and the parents. These tests should be embedded in an ethical 
framework based on the principles of beneficence and respect for autonomy. Beneficence-
based clinical judgements should be evidence-based (that is, they should be based on the 
best available evidence), and clinical strategies should be identified that are reliably expected 
to result in the greatest balance of benefits (that is, the protection and promotion of health-
related interests) over clinical harms (that is, impairments of those interests)189. Respect for 
autonomy and the patient’s perspective is another key issue in the context of perinatal 
genetic testing. The physician is obliged to respect the parents’ values and beliefs, to respect 
their perspective on their interests and to implement only those clinical strategies that are 
authorized as a result of informed consent30,189.
Bergmann et al. Page 17
Nat Rev Dis Primers. Author manuscript; available in PMC 2019 June 25.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Management
ADPKD
ADPKD is a systemic disorder with renal manifestations and an increasing number of 
extrarenal manifestations (TABLE 1). Management of ADPKD was the subject of a report 
of a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference44, 
Spanish and Kidney Health Australia-Caring for Australasians with Kidney Impairment 
(KHA-CARI) management guidelines and a Core Curriculum190. Additionally, a 
classification of ADPKD disease severity into different classes (1A–1E) was developed on 
the basis of htTKV (which provides an accurate estimate of kidney cyst burden in ADPKD) 
and age178. The classification stratifies patients on the basis of the rate of GFR decline and is 
useful in clinical trials to identify patients with rapid disease progression who might benefit 
most from therapy, as opposed to patients whose disease progresses slowly and who might 
not need therapy191.
Lifestyle interventions to enhance hydration, limit dietary sodium and protein intake and 
maintain a healthy weight, as well as early detection and rigorous treatment of hypertension 
and possibly dyslipidaemia, might have a beneficial effect on the course of the disease. 
Patients with ADPKD often have a mild urinary concentration defect that usually goes 
undetected, which is consistent with the inappropriate antidiuresis that is observed in Pkd1 
heterozygous mice192. Plasma vasopressin and its precursor copeptin, which serves as a 
marker of vasopressin, may be increased in patients with ADPKD, and plasma copeptin 
levels correlate with the severity of ADPKD in cross-sectional studies and with the rate of 
disease progression in prospective studies193. Increasing evidence has shown that the action 
of vasopressin on the kidneys may contribute not only to the progression of ADPKD but also 
to the progression of CKD in general194. Additionally, two large studies on cyst and kidney 
growth (the CRISP study) and hypertension (the HALT study) in ADPKD have shown an 
association between dietary salt intake and the rate of progression of ADPKD195. The 
CRISP and the Modification of Diet in Renal Disease (MDRD) studies suggested an 
association between low levels of high-density lipoprotein (HDL) cholesterol and faster rates 
of kidney growth or GFR decline, respectively, in patients with ADPKD195. Experimental 
studies have shown that moderate food or caloric restriction substantially inhibits disease 
progression in orthologous mouse models of ADPKD, and high body mass index in patients 
with ADPKD is associated with a poor outcome196.
Treatments that directly target cystogenic mechanisms (such as decreasing cAMP levels in 
cystic tissues) are now available. For example, the Tolvaptan Efficacy and Safety in 
Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes 
(TEMPO) 3:4 clinical trial showed that the vasopressin receptor 2 antagonist tolvaptan 
slowed the rate of kidney growth and estimated GFR (eGFR) decline in patients with early 
ADPKD (age 18–50 years, estimated creatinine clearance ≥60 ml min–1)197; tolvaptan has 
received regulatory approval in Japan, Canada, the European Union, Switzerland and South 
Korea for the treatment of ADPKD in patients with rapidly progressive disease. In the USA, 
approval from the US FDA was deferred until further data are available on the potential 
benefits and risks of tolvaptan treatment. The Replicating Evidence of Preserved Renal 
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Function: an Investigation of Tolvaptan Safety and Efficacy in ADPKD (REPRISE) clinical 
trial showed that tolvaptan also slows the eGFR decline in later-stage ADPKD (age 18–65 
years, eGFR 25–65 ml/min/1.73 m2)198, and the FDA has now approved the therapy in the 
USA. In both the TEMPO 3:4 and REPRISE trials, clinically significant elevation of serum 
transaminases was detected in ~5% of patients who were treated with tolvaptan; therefore, 
strict instructions to regularly monitor liver enzymes are incorporated into the treatment 
regimen. Potential benefits and adverse effects of tolvaptan treatment should be considered 
before prescribing tolvaptan, and the treatment is also recommended only for patients with 
rapidly progressive disease199.
In the ALADIN study on kidney and cyst growth, patients with ADPKD were randomly 
assigned to octreotide (a long-acting somatostatin analogue that also decreases cAMP levels) 
or placebo treatment groups, and a favourable trend of reduced TKV increase and eGFR 
decline was observed, although statistical significance was not reached and thus larger trials 
are required200. DIPAK1 and LIPS are ongoing clinical trials to evaluate the effect of the 
somatostatin analogue lanreotide on disease progression in patients with ADPKD and stage 
3 CKD or stage 2–3 CKD, respectively. Clinical trials of the mTOR inhibitors sirolimus and 
everolimus failed to show benefit despite encouraging results in animal models201–203, 
which is probably owing to an inability to administer sufficient levels of these drugs to 
inhibit mTOR in the kidneys without causing systemic toxic effects. Pravastatin, an HMG-
CoA reductase inhibitor, has shown promising results in slowing cyst growth in a small 
randomized clinical trial in children with ADPKD204.
Cyst growth and disease monitoring.—Cyst development and growth varies widely 
between patients. Furthermore, even in patients with severe disease, GFR remains within the 
normal range for decades, limiting its value to estimate the prognosis or monitor the 
progression of the disease in its early stages. TKV correlates with disease manifestations 
such as hypertension, pain, haematuria and proteinuria159; TKV and cyst volume increase 
exponentially but at variable rates, averaging 5–6% per year. Accordingly, measurement of 
TKV is beneficial if the data could influence a medical decision, such as enrolment in a 
clinical trial or initiation of treatment in countries in which medications are approved for the 
treatment of ADPKD. MRI is the preferred method to measure TKV, as it is more accurate 
than ultrasonography and safer than CT, but its cost may be a limitation in some countries.
Hypertension.—A recent meta-analysis concluded that at least 20% of children with 
ADPKD have hypertension and that many of those children are undiagnosed and do not 
attend regular follow-ups177. A recent retrospective multicentre study of ambulatory blood 
pressure monitoring even found a higher prevalence of hypertension in children with 
ADPKD176. In this study, 31%, 42% and 35% of a cohort of 310 children with ADPKD 
(mean age 11.5 ± 4.1 years) were hypertensive during the daytime, the night-time or the 
entire 24-hour cycle, respectively. More than half of the patients (52%) lacked physiological 
nocturnal blood pressure dipping. Thus, children with a family history of ADPKD should be 
screened regularly for hypertension from the age of 5 years and at 3-year intervals when no 
hypertension is found. The HALT PKD placebo-controlled clinical trial examined the role of 
blockade of the RAAS in patients with early and advanced ADPKD. In patients with early 
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ADPKD (15–49 years of age, eGFR >60 ml/min/1.73 m2), rigorous blood pressure control 
(blood pressure target range 95/60 to 110/75 mmHg) was associated with slower rates of 
increase in TKV and renal vascular resistance and with a greater decline in left ventricular 
mass index (faster during the first 4 months and slower decline there-after), without an 
overall effect on eGFR, than standard blood pressure control (120/70 to 130/80 
mmHg)205,206. Rigorous blood pressure control was not studied in patients with more 
advanced ADPKD (18–64 years of age, eGFR 25–60 ml/min/1.73 m2) because it was 
considered to be detrimental in these patients207. At both early and late stages of the disease, 
monotherapy with an angiotensin-converting-enzyme (ACE) inhibitor achieved good blood 
pressure control (<130/85 mmHg) in most patients. Therefore, ACE inhibitors (or 
angiotensin receptor blockers (ARBs)) are considered to be the first-line therapy for 
hypertension in ADPKD.
Pain.—At least 60% of patients with ADPKD eventually experience acute or chronic 
abdominal or flank pain of renal origin. Acute pain is often associated with kidney cyst 
haemorrhage, infection or nephrolithiasis (kidney stones). Chronic pain is usually 
attributable to cyst enlargement that causes kidney capsule stretching or to marked 
enlargement of the kidneys and/or liver that causes musculoskeletal back pain. Managing 
chronic pain can be challenging and requires a multidisciplinary stepwise approach with 
multiple strategies, including physical therapy interventions, pain medications, cyst sclerosis 
and laparoscopic cyst fenestrations and renal denervation procedures208–210.
Haematuria.—Gross haematuria may be associated with cyst haemorrhage or infection, 
passage of kidney stones or kidney or urinary tract neoplasms. Cyst haemorrhage can be 
associated with fever, which might be difficult to differentiate from cyst infection. With 
conservative management (rest, holding anticoagulants or antiplatelet drugs, and analgesics 
if needed), most haemorrhages resolve within 2–7 days. If symptoms persist for >1 week or 
if the initial episode occurs after the age of 50 years, investigation to exclude neoplasm 
should be undertaken. The management of gross haematuria is mostly conservative — rest, 
hydration and avoidance or temporary holding of medications that facilitate bleeding. The 
antifibrinolytic agent tranexamic acid can be considered when conservative therapy fails211. 
Selective arterial embolization or nephrectomy may be necessary in cases of life-threatening 
haemorrhage.
Nephrolithiasis.—Increased frequency of nephrolithiasis in patients with ADPKD is 
attributed to increased urinary stasis and metabolic factors, which include low urinary pH, 
low citrate concentration and decreased ammonia excretion. These factors predispose to the 
development of uric acid and calcium oxalate stones. The medical treatment of 
nephrolithiasis in patients with ADPKD is similar to that in the general population; for 
example, extracorporeal shock wave lithotripsy and percutaneous nephrolithotomy in 
patients with early disease and normal kidney function have been used successfully without 
increased risk of complications212. Flexible ureterorenoscopy with laser fragmentation has 
also been used successfully213.
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Cyst infection.—The triad of abdominal or flank pain and/or tenderness, fever and 
elevated erythrocyte sedimentation rate or C-reactive protein (CRP) should raise suspicion of 
cyst infection. Initial evaluation should include urinalysis, urine culture with antimicrobial 
susceptibility testing, blood culture and imaging with CT scan or MRI214,215. When 
available, an 18F-fluorodeoxyglucose (FDG)–PET scan is more sensitive than CT or MRI for 
detecting cyst infections216. If a complex cyst (that is, a cyst that does not meet the 
diagnostic criteria of a benign simple cyst) is detected, aspiration of cyst fluid should be 
considered if clinically feasible and the fluid should be sent for microbiology studies. 
Treatment of cyst infections should include intravenous broad-spectrum antibiotics if the 
patient has systemic symptoms, followed by a transition to oral antibiotics that have good 
cyst penetration, such as ciprofloxacin or other quinolones (total duration of antibiotic 
treatment should be at least 4 weeks). If the fever persists unabated for >72 hours, repeat 
imaging should be obtained to exclude complications that may require intervention (for 
example, perinephric abscess or urinary tract obstruction). Infected cysts >5 cm may be 
resistant to antibiotic therapy and require percutaneous or surgical drainage217. Perinephric 
abscess requires prolonged intravenous antibiotic therapy and drainage should be 
considered. Nephrectomy is rarely needed but may be considered in cases of perinephric 
abscess or emphysematous pyelonephritis that are resistant to drainage and/or antibiotic 
therapy218.
Renal cell carcinoma.—A high index of suspicion is required to make the diagnosis of 
renal cell carcinoma (RCC) in the rare cases when a tumour develops in a polycystic kidney, 
as RCC does not occur more frequently in ADPKD than in other renal diseases219. Rapid 
growth of a complex cyst, a solid mass on ultrasonography, speckled calcifications on CT 
imaging, contrast enhancement, tumour thrombus and regional lymphadenopathies on CT or 
MRI scans should raise suspicion of RCC. Fever and systemic symptoms (anorexia, fatigue 
and weight loss) are frequent presenting symptoms220. Nephronsparing interventions should 
be used whenever feasible and safe221.
ESRD.
Kidney transplantation is the optimal kidney replacement treatment and the results in 
ADPKD patients are better than in the general ESRD population222. Given the natural 
course of the disease, preemptive transplantation can be planned and is associated with 
better outcomes. Radical nephrectomy for space considerations is carried out in 20–25% of 
patients with ADPKD and may be done before, at the time of or several months after the 
transplantation. During the first year following a successful kidney transplantation, the 
volume of the native polycystic kidneys decreases by 30–40%223 for reasons that are unclear 
but might include reduced blood flow and resolution of uraemic factors that stimulate renal 
growth. Indications for nephrectomy also include recurrent and/or severe infection, bleeding, 
intractable pain, symptomatic nephrolithiasis and suspicion of kidney malignancy. Hand-
assisted laparoscopic nephrectomy is less invasive than an open approach and the preferred 
timing varies between centres224.
Although ADPKD is not a contraindication for peritoneal dialysis225, it is less commonly 
used than haemo-dialysis given the challenge of accommodating a large volume of 
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peritoneal dialysate and an increased risk of abdominal wall hernias. In haemodialysis 
treatment, patients with ADPKD may have an increased risk of aneurysmal dilatation of 
arteriovenous fistulas225.
Hepatic cysts.—In the majority of patients with ADPKD, liver cysts remain 
asymptomatic. Because of the increased survival of patients with ADPKD on RRT, the 
prevalence of clinically significant PLD is increasing226. Manifestations of PLD may be due 
to mass effects from organomegaly or cyst complications such as haemorrhage, infection or 
rupture. In addition to female sex, the main risk factors for severe PLD include multiple 
pregnancies and prolonged use of estrogens and, possibly, progestogens227.
Surgical interventions for severe PLD should target symptom alleviation and improvement 
of QOL and should be tailored to the characteristics of individual patients and to the natural 
history of PLD68. Surgical options include percutaneous aspiration and sclerosis with 
ethanol or other agents, deroofing of cysts laparoscopically or by open surgery and 
combined liver resection and cyst fenestration228. The latter procedure should be reserved 
for patients with severe symptomatic PLD and a liver anatomy that allows the preservation 
of at least two contiguous liver segments with adequate hepatic venous drainage229. 
Transcatheter arterial embolization results in only a modest volume reduction and is 
associated with substantial morbidity and mortality230,231. Liver transplantation is 
considered for patients when partial liver resection is not feasible. Somatostatin analogues, 
such as octreotide and lanreotide, can reduce liver cyst volume232–236.
Liver cyst infections are a common complication of PLD and are diagnosed, evaluated and 
managed similarly to infected kidney cysts. Diverticular disease and ascending cholangitis 
should be considered as a possible source of liver cyst infections. The presentation of 
ascending cholangitis is characterized by cholestasis with elevation of conjugated bilirubin. 
Some patients may experience recurrent episodes of cholangitis that may be difficult to treat, 
sometimes requiring monthly rotating antibiotics to prevent recurrences. Endoscopic 
sphincterotomy may increase the risk of recurrent cholangitis and should be avoided if 
possible. It is important to recognize that mild dilatation of the extrahepatic common bile 
duct can be observed in up to 40% of patients with ADPKD and should not lead to an 
unnecessary and dangerous sphincterotomy237.
Intracranial aneurysms.—ICAs are detected in ~8% of patients with ADPKD, which is 
approximately fivefold higher than in the general population but is further increased 
(approximately threefold higher) in patients with a relative who has had an ICA238.
The rupture of ICAs is associated with a mortality of up to 50% and a mean age at rupture of 
40 years, which is lower than in the general population238. Rupture usually presents as 
sudden onset of a severe headache (described as a thunder clap headache). Increased size, 
posterior location, family history of ICAs and a personal history of subarachnoid 
haemorrhage are potential risks for rupture. The management of unruptured ICAs is the 
same as that in the general population69,239,240.
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Given the frequency of ICAs in patients with ADPKD and that they increase morbidity and 
mortality risk, whether patients with ADPKD should undergo presymptomatic screening for 
ICAs has been intensely debated and universal consensus has not been reached239,241. The 
majority of ICAs that were detected by presymptomatic screening in patients with ADPKD 
(which is generally carried out using magnetic resonance angiography (MRA)) are <7 mm in 
diameter and are in the anterior circulation (80–90% of cases), which in the general 
population have a very small risk of rupture239. Few longitudinal studies of asymptomatic, 
unruptured ICAs in patients with ADPKD have been carried out, but the few that have 
suggest that their natural history is not different from that of ICAs in the general 
population69,242. Accordingly, although we do not recommend presymptomatic screening 
for all patients with ADPKD, screening might be appropriate in patients with a family 
history of aneurysmal rupture owing to the higher prevalence of unruptured ICAs and 
possible increased risk of rupture243,244. Screening may also be appropriate in patients with 
ADPKD who have a family history of ICAs and a personal history of intracranial 
haemorrhage, as well as in individuals in high-risk professions such as pilots and before 
major elective surgeries. Given the substantial risk of intervention, it is our opinion that 
treatment is not usually recommended for ICAs <7 mm in size; the frequency of follow-up 
MRAs for smaller ICAs depends on information about stability. If screening is negative, 
rescreening of patients with good life expectancy at 5-year intervals seems reasonable in our 
opinion. MRA for the detection of ICAs does not require administration of gadolinium and 
is preferable to CT angiography (CTA), especially in patients with reduced eGFR to avoid 
iodinated contrast245.
ARPKD
In the most severe cases of ARPKD, poor urine output in utero results in oligohydramnios 
(deficiency of amniotic fluid) and Potter sequence. The ARPKD presentation at birth may be 
dominated by respiratory difficulties from pulmonary hypoplasia and/or from restrictive 
disease caused by massive kidney enlargement1. In patients with respiratory insufficiency, 
the cause should be identified and aggressive resuscitative measures, including artificial 
ventilation if needed, should be implemented. In some severe cases, unilateral or bilateral 
nephrectomies may be considered, although the evidence to support this approach has been 
questioned183,246. In patients who survive infancy, renal function may improve or remain 
stable for many years and slowly progress to renal failure only later in life as the kidneys 
develop macroscopic cysts and interstitial fibrosis, and the size ofthe kidneys relative to 
body mass often decreases182,183.
Hypertension.—Arterial hypertension often develops during the first months of life and 
affects up to 80% of children with ARPKD32. Although arterial hypertension is sometimes 
difficult to control, even with multidrug treatment, it generally responds well to salt 
restriction and antihypertensive drugs (preferably an ACE inhibitor or ARB). After the first 
year of life, hypertension may become easier to control for reasons that are still poorly 
understood.
Electrolyte, nutritional and growth abnormalities.—Electrolyte abnormalities due to 
the inability to concentrate and dilute urine are very common in the early, severe 
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presentations of ARPKD and should be anticipated and treated183. An assertive nutritional 
programme and correction of acidosis are important to optimize linear renal growth. If renal 
growth impairment occurs, treatment with growth hormone can be considered247.
ESRD.—For infants with ESRD, peritoneal dialysis or haemodialysis can be used. Renal 
transplantation is limited by body size, but in centres that are well experienced in paediatric 
surgery, it can be carried out even in small children with a minimum weight of 7 kg248,249. 
Rejection rates and survival beyond 3 years of age are not different from patients with most 
other renal diseases who undergo transplant surgery. Biliary sepsis can cause mortality in 
patients with ARPKD after renal transplantation249.
Congenital hepatic fibrosis.—Although CHF invariably occurs in children with 
ARPKD and can be associated with non-obstructive intrahepatic bile duct dilatation (Caroli 
disease), clinical manifestations of portal hypertension typically manifest as the children 
age. Some adolescents and adults without a previous diagnosis of ARPKD may present with 
hepatic manifestations, most often with complications of portal hypertension (such as 
variceal oesophageal bleeding, splenomegaly and hypersplenism with leukopenia, 
thrombocytopenia or anaemia) or episodes of cholangitis or sepsis and complications of 
biliary sludge or lithiasis. Liver enzyme values can occasionally be mildly elevated, but 
hepatocellular function is usually normal. The kidneys in these patients may be normal or 
exhibit varying degrees of medullary collecting duct ectasia or macrocystic disease without 
marked renal enlargement. Patients with ARPKD who survive infancy and those who 
present during adolescence may require a portosystemic shunt to prevent life-threatening 
haemorrhages from oesophageal varices. Patients with associated Caroli disease might have 
recurrent episodes of cholangitis. Although routine antibiotic prophylaxis for cholangitis is 
not recommended, antibiotic prophylaxis for 6–12 weeks after a cholangitis episode, 
immediately after transplantation or in the context of increased immunosuppression may be 
considered249. Adult patients with ARPKD >40 years of age may have a slightly increased 
risk of developing hepatic tumours, especially cholangiocarcinomas250.
Combined kidney and liver transplantation has been advocated for selected patients with 
ESRD who have substantial bile duct dilatation and episodes of cholangitis251–253. In 
addition to primary hyperoxaluria, ARPKD can certainly be considered an indication for 
combined liver and kidney transplantation during childhood. The best timing and strategy 
for combined transplantation is still a matter of debate and usually requires decision-making 
based on individual circumstances.
Quality of life
In the personalized medicine approach, it is no longer sufficient to treat the disease — 
instead, clinicians must treat their patients. Consequently, disease management paradigms 
should include biological, physical and psychological assessments, which seems to be 
particularly important for patients with multifaceted diseases such as ADPKD and further 
underscores the importance of including patient-reported outcomes in routine clinical care. 
In parallel, sensitive and appropriate kidney disease measures should be developed alongside 
other established tools to assess the burden of ADPKD in an individualized, personalized 
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manner. Health-related QOL (HRQOL), which encompasses physical and mental health, 
social issues as well as pain and discomfort254, facilitates patient-centred care and 
encourages shared decision-making among medical professionals and patients. The specific 
issues of QOL have not been systemically studied in patients with ARPKD or their families; 
accordingly, we focus on only ADPKD.
ADPKD affects the biological, physical and psychological aspects of patient QOL. For 
example, physicians underestimate the effect of renal pain in patients with ADPKD, despite 
its high prevalence in patients with chronic kidney diseases255. Pain and abdominal fullness, 
which are both common symptoms of ADPKD, are often associated with lower eGFR256. 
Furthermore, pain is independently associated with clinical depression257, and although 
evidence exists that depression is common among patients with ADPKD257, studies that 
explicitly address the treatment of depression in patients with ADPKD are lacking. 
Accordingly, HRQOL assessment might help guide treatment decisions. Indeed, HRQOL 
scores have been shown to predict risk of increased hospitalization and mortality in patients 
with chronic kidney diseases258. However, only a limited number of HRQOL studies of 
patients with ADPKD have analysed possible correlations between disease progression, 
psychosocial burden and their effect on daily living.
Generic QOL measures (such as the 36-item Short Form Health Survey (SF-36)) are fairly 
insensitive, especially in patients with early-stage ADPKD255,256,259. In a recent study of 
HRQOL in patients with ADPKD who encompassed all stages of the disease (from patients 
with early CKD to those on dialysis or undergoing renal transplantation), overall HRQOL 
was generally highest in patients with CKD stage 1–3, followed by renal transplant 
recipients, patients with stage 4–5 CKD and patients on dialysis255. Progressive disease 
predominantly had an effect on physical health, whereas mental health varied less between 
patients with different stages of the disease255.
A new self-administered patient-reported outcome questionnaire, the ADPKD Impact Scale 
(ADPKD-IS), which consists of 14 items representing 3 conceptual domains (physical, 
emotional and fatigue) and 4 additional questions, was developed on the basis of the 
information (see below) of 1,674 patients worldwide260. The ADPKD-specific conceptual 
framework (a model representing concepts and themes to be measured and their 
relationships) in this questionnaire was created on the basis of information from patients and 
clinical experts about how ADPKD affected the general health, daily activities, physical or 
social activities, pain experience, urinary issues (such as urgency and frequency of urination 
as well as nocturia) and emotional well-being of patients. Scores on the physical, emotional 
and fatigue domains of the ADPKD-IS differed substantially between patients with stage 3b 
CKD versus those with stage 1 CKD at baseline260.
Of note, effective treatment of ADPKD can improve HRQOL — a 1-year trial with 
octreotide resulted in modestly reduced liver volumes (4.95% ± 6.77%) and was associated 
with improvements in pain and emotional scales on the SF-36 (REF.234). Perceived social 
support and the psychosocial impact of coping with a diagnosis of ADPKD were analysed in 
another cross-sectional study257, which found that lower eGFR was associated with less 
perceived social support. Depression, increased kidney size and loss of a first-degree relative 
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to ADPKD were identified as independent risk factors for increased psychosocial risk. Of 
note, women were more likely to be predisposed to poorer overall psychosocial well-being 
than men257.
Given the genetic basis of ADPKD, patients are often faced with major psychological 
challenges related to the hereditary nature of the disorder and its potential effect on their 
family and offspring. ‘Genetic guilt’ may be the reason many patients hide their diagnosis 
from their spouse and family, even when these people are usually central to their emotional 
support network. Hidden genetic guilt substantially affects the psychosocial well-being of 
patients261.
Outlook
Although the prospects for better outcome predictions and treatments have dramatically 
improved over the past decade, an incomplete understanding of the function of the 
polycystin proteins remains a substantial impediment to understanding the pathogenesis of 
PKD and developing rational therapies to treat these diseases. For ARPKD in particular, the 
limitations of experimental models and the paucity of biomarkers and imaging modalities to 
enable prediction of the disease course limit current efforts to design clinical trials to test the 
efficacy of potential new therapies.
Pathogenesis
The greatest challenge in research on PKD, and that which is likely to be of greatest benefit 
if overcome, is understanding the pathogenesis of PKD. Although the aetiologies of ADPKD 
and ARPKD are mostly understood, many questions about the pathogenesis of these 
diseases are still intensely disputed. For example, although PC2 is a TRP-like calcium 
channel, a definite role for Ca2+ in the pathogenesis of ADPKD has not been established, 
and the role of PC2 as a chaperone for PC1 may be important262,263. The role of somatic 
changes at the disease-causing locus in cystic epithelia, which are required for cyst initiation 
and, more importantly, for cyst expansion and/or persistence, is another highly debated area 
of research that would benefit from additional studies56,62,63,264.
The ciliary basis of PKD pathogenesis has been the predominant hypothesis for >15 years, 
but studies have cast doubt on this hypothesis. The proposed ciliary localization (among 
others) of PC1, PC2, fibrocystin and DZIP1L132,145 and the observations that a loss of 
ciliary function265 or the abnormal ciliary composition in some syndromic 
ciliopathies266,267 cause PKD are the strongest evidence supporting the cilia hypothesis. 
However, the role of the polycystin complex in cilia is not clear; for example, the hypothesis 
that the polycystin complex functions as a mechanosensor in cilia is not supported by recent 
data86,87. Indeed, despite a study suggesting that the polycystin complex is a WNT receptor, 
the function of the polycystin complex in healthy tissue seems far from resolved and this 
uncertainty remains a major impediment to understanding the pathogenesis of ADPKD268. 
As discussed earlier, cilia certainly have a role in PKD, as concomitant ablation of Pkd1 and 
loss of cilia in mice results in less severe cystic disease than ablation of Pkd1 alone103. 
Alternatively, separate cystic (polycystin complex-related) and proliferation pathways 
required for cystic growth are ciliary-based. In fact, the ciliary localization of PC1 has been 
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questioned (a specific stimulus might be required for PC1 to get to the cilium), and other 
polycystin-like proteins (such as PKD1-like protein 1 (PKD1L1) and PKD2L1), rather than 
PC1 and PC2, might regulate ciliary Ca2+ levels87,269,270. In addition, conflicting data exist 
about whether calcium influx into the cilium is sufficient to activate a cytoplasmic calcium 
response87,271.
Although a ciliary function has been proposed for both fibrocystin and DZIP1L, and genetic 
studies suggest that they are associated with the polycystin complex121,132, the precise role 
of these proteins remains unresolved. That fibrocystin seems much more important for 
kidney tubule integrity in humans than in mice further complicates experimental 
resolution272,273. The functions of PC1, PC2, fibrocystin and DZIP1L, or those of the 
cleavage products of these proteins, when secreted into urine in soluble form148 or in urinary 
extracellular vesicles exocytosed by the multivesicular body pathway274, or even possibly 
from cilia275, require further study. Other unresolved questions include whether the C 
terminus of PC1 (and fibrocystin) is cleaved and translocates to the nucleus, how much it 
contributes to the signalling by the polycystin complex and whether it is relevant for 
preventing PKD276. Additionally, ciliary-based signalling, such as that mediated by sonic 
hedgehog, has also been suggested to be important in PKD, although its precise role in 
ADPKD and ARPKD is not clear277.
Diagnosis and prognosis
Further research is necessary to improve the identification of patients who require treatment 
and especially the monitoring of treatment efficacy. It is widely accepted that current 
methods to monitor kidney function are not very useful for diagnosis in the early stages of 
disease when treatment is likely to be the most efficacious. Determination of htTKV by 
imaging is currently the best method to predict disease outcomes and to monitor treatment 
efficacy, and further quantitative image analysis of kidney composition is likely to improve 
its predictive and monitoring value278. Research to identify potential biochemical 
biomarkers is still in the early stages, but with an easily accessible supply of urine from 
patients to monitor kidney function, it seems likely that this area of research is ripe for 
development279,280. Together with the present genic and allelic predictive value of the 
germline mutation, better in silico analyses and cellular assays should enable the identity 
and penetrance of in-frame mutations to be more accurately predicted262. Other genetic 
factors that are associated with disease progression (identified using genome-wide 
association studies, WES and WGS) are also likely to be of prognostic value and to improve 
our understanding of the pathogenesis of PKD79.
Therapies
This is an exciting time for PKD studies, as the first drug specifically for the treatment 
ADPKD, tolvaptan, has received regulatory approval in many parts of the world179,197. It 
seems likely that other treatments targeting signalling pathways downstream of PKD-
causing genetic lesions, including inhibitors of cAMP generation (for example, somatostatin 
analogues such as octreotide200), more effective inhibitors of mTOR activity in the kidneys 
(for example, rapamycin conjugates281), remedying metabolic abnormalities (for example, 
by food restriction282) and other therapies that were effective in rodent studies (for example, 
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reducing inflammation or calcium signalling; reviewed elsewhere33), are likely to be 
approved for human treatment in the next few years. There are prospects for combination 
treatments283, and some of these therapies may also be effective in treating severe PLD284. 
Furthermore, although the development of treatments that more directly target the basic 
defect (deficiency of PCI or PC2) in PKD has not been undertaken, evidence exists for other 
genetic diseases that this approach could be productive285–287. These treatments could 
include chaperone treatment for some missense mutations288, targeting nonsense mutations 
using translational readthrough-inducing drugs289, boosting the levels of functional PC1 and 
somatic gene editing using CRISPR–Cas9 (REF.290) to repair the underlying defect in the 
kidneys. To date, little progress has been made in developing treatments for ARPKD, but 
given the related disease mechanisms in ADPKD and ARPKD, there is the hope that at least 
some therapies for ADPKD might also be effective in treating ARPKD.
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Box 1 |
Indications for genetic testing in ADPKD
• In a young relative who is a potential kidney donor for a patient with 
autosomal dominant polycystic kidney disease (ADPKD), especially if one or 
two cysts are detected by imaging methods — to exclude genetically affected 
relatives291.
• In individuals with a negative family history — to establish a firm diagnosis 
or to test for mosaicism74 (note that at least 10–15% of families with ADPKD 
can be traced to a new (de novo) mutation).
• In cases of polycystic kidney disease of unknown origin and a negative family 
history — to assess recurrence risk and for family planning47.
• In patients with very early-onset disease — to identify biallelic disease or 
other complex genetics59,248,292.
• In patients with mild disease — to establish whether the disease is genetic and 
its cause292.
• In patients who are starting treatment or are being considered for a clinical 
trial — to establish a firm diagnosis and help determine whether the disease is 
rapidly progressive.
• In all patients with ADPKD — if treatment is fairly inexpensive and reliable, 
most patients can obtain a firm diagnosis and prognostic information.
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Fig. 1 |. Renal and extrarenal manifestations in polycystic kidney disease.
a | Autosomal dominant polycystic kidney disease (ADPKD) is the most common form of 
polycystic kidney disease (PKD) and is mainly caused by mutations in PKD1 and PKD2, 
which encode polycystin 1 and polycystin 2, respectively. ADPKD is usually an adult-onset 
disease that is characterized by the formation of fluid-filled cysts in various locations in the 
kidneys, but mostly in the distal regions. The histology image is of the kidney (stained with 
Malloy trichrome stain) of a 49-year-old patient with end-stage ADPKD. Small cysts and 
extensive fibrosis (blue) are visible. b | Autosomal recessive PKD (ARPKD) is rarer and 
more severe than ADPKD and is caused by mutations in polycystic kidney and hepatic 
disease 1 (PKHD1; which encodes fibrocystin) and DZIP1L (which encodes DAZ-
interacting protein 1-like protein (DZIP1L)). ARPKD usually presents in utero, perinatally 
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or in infancy and is characterized by the formation of cysts from the renal distal tubules and 
collecting ducts. Microscopically, cysts are fusiform dilatations of the aforementioned distal 
parts of the nephron, which are lined by a columnar or cuboidal epithelium. Respective 
dilated collecting ducts run perpendicular to the renal capsule (renal section is stained with 
haematoxylin and eosin). Both diseases often progress to end-stage renal disease (ESRD) 
that requires renal replacement therapy. GFR,glomerular filtration rate.
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Fig. 2 |. Domain organization of proteins implicated in polycystic kidney disease.
The structure of polycystin 1 (PC1), polycystin 2 (PC2), the membrane-bound form of 
fibrocystin and DAZ-interacting protein 1-like protein (DZIP1L) are depicted (not to scale). 
PC1 and PC2 are multispan membrane proteins that form a complex that is localized to 
multiple subcellular locations, including the primary cilium. Fibrocystin is also localized to 
the primary cilium and is subject to Notch-like proteolytic processing, resulting in release of 
the carboxy-terminal tail, which can translocate to the nucleus and may regulate gene 
expression. DZIP1L is a soluble zinc-finger protein that is localized to the centrioles and 
basal bodies at the ciliary transition zone. CC, coiled coil; C flank, carboxyl flank; C 
terminus, carboxyl terminus; ER, endoplasmic reticulum; GPCR, G protein-coupled 
receptor; LRR, leucine-rich repeat; N flank, amino flank; N terminus, amino terminus; PKD, 
polycystic kidney disease. Adapted from REF.293, Springer Nature Limited.
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Fig. 3 |. The dosage model of cystogenesis in autosomal dominant polycystic kidney disease.
The level of functional polycystin 1 (PC1; encoded by PKD1) directly influences the renal 
phenotype in patients with autosomal dominant polycystic kidney disease (ADPKD) — an 
~50% reduction in PC1 levels (for example, from haploinsufficiency due to a single 
inactivating allele) is associated with adult-onset PKD, whereas the complete absence of 
PC1 is lethal. Furthermore, incompletely penetrant (hypomorphic) PKD1 alleles of different 
strengths and combinations also influence the renal phenotype. For example, the PKD1Y528C 
allele results in a phenotype similar to that in patients with mutations in PKD2, whereas the 
PKD1R3277C allele can result in a phenotype that ranges in severity from just a few cysts to 
adult-onset disease to early-onset disease, depending on which PKD1 allele is present in 
trans. Additional mutations and/or variants of the disease-causing locus and somatic and 
germline mutations at other loci, as well as chance and environmental factors, influence the 
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disease course by determining the frequency of cyst development and their progression. 
Adapted with permission from REF.294, Elsevier.
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Fig. 4 |. Mechanisms of cyst formation and expansion.
Polycystin 1 (PC1) and PC2 form a multimeric protein complex that is localized to several 
cellular compartments, including cell–cell junctions, cell–matrix interfaces and in the 
primary cilium (part a; the ciliary localization of the polycystins is shown in part b). The 
polycystin proteins are also post-translationally modified, which regulates their transport, 
localization and/or function52,121,288,295. In addition, many proteins have been reported to 
bind directly to polycystin proteins; for example, PC1 and fibrocystin bind to PC2 and 
modulate its channel activity53,296,297. Furthermore, DAZ-interacting protein 1-like protein 
(DZIP1L) interacts with septin 2 (SEPT2; in the septin ring), a protein implicated in 
maintenance of the periciliary diffusion barrier at the ciliary transition zone. Consistent with 
a defect in the diffusion barrier, the localization of PC1 and PC2 to the ciliary membrane is 
compromised in DZIP1L-mutant cells, suggesting that DZIP1L is required for regulating the 
integrity of the transition zone. How PC1, PC2, fibrocystin and DZIP1L directly affect 
cellular signalling is not known with certainty. However, these proteins modulate several 
signalling pathways, which in turn control essential cellular functions, such as proliferation, 
apoptosis, cell adhesion and differentiation54. Reduced Ca2+ influx, increased cAMP levels 
and aberrant activation of RAS–RAF–ERK signalling in renal epithelial cells are important 
mediators of cyst growth. Other proposed mechanisms that regulate cystogenesis and/or cyst 
growth include altered signalling mediated by G proteins, mechanistic target of rapamycin 
(mTOR), phosphoinositide 3-kinase (PI3K)–AKT, AMP-activated protein kinase (AMPK), 
Janus kinase 2 (JAK2)–signal transducer and activator of transcription 1 (STAT1; or STAT3 
or STAT6), nuclear factor of activated T cells (NFAT) and nuclear factor-κB. In addition, 
cyst expansion is accompanied by changes in cellular metabolism, such as a switch to 
aerobic glycolysis as well as impaired fatty acid oxidation. AC6, adenylyl cyclase 6; AVP, 
arginine vasopressin; CFTR, cystic fibrosis transmembrane conductance regulator; EGFR, 
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epidermal growth factor receptor; ER, endoplasmic reticulum; IFT, intraflagellar transport; 
PDE1, phosphodiesterase 1; PKA, protein kinase A; PKD, polycystic kidney disease; SST, 
somatostatin; SSTR, somatostatin receptor; V2R, vasopressin V2 receptor.Part a is adapted 
from REF.293, Springer Nature Limited. Part b is adapted from REF.298, Springer Nature 
Limited.
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Fig. 5 |. Renal fibrosis in autosomal dominant polycystic kidney disease.
Altered expression of cystic proteins and dysregulated signalling in renal epithelial cells 
affect cell–extracellular matrix interactions and induce the production of chemokines (such 
as monocyte chemotactic protein 1 (MCP1), CC-chemokine ligand 6 (CCL6), CCL28, CXC-
chemokine ligand 1 (CXCL1), CXCL8 and CX3C-chemokine ligand 1 (CX3CL1)), pro-
inflammatory cytokines (such as tumour necrosis factor (TNF), IL-1, IL-2, IL-6, IL-8, 
macrophage colony-stimulating factor 1 (CSF1) and macrophage migration inhibitory factor 
(MIF)), profibrotic growth factors (such as transforming growth factor-β (TGFβ), TGFα, 
epidermal growth factor (EGF), fibroblast growth factors (FGFs) and platelet-derived growth 
factor (PDGF)) and proteins involved in matrix remodelling (such as matrix 
metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs))299,300. 
These changes result in the accumulation of extracellular matrix and the recruitment of 
inflammatory cells, which is already observed in the early stages of the disease. In particular, 
M1 and M2 macrophages are important contributors to disease progression. Macrophages 
and interstitial fibroblasts also produce cytokines, and abnormal cytokine-mediated crosstalk 
between renal epithelial cells and inflammatory cells results in a positive feedback loop of 
increasing fibrosis.
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Fig. 6 |. Hepatobiliary lesions in hepatorenal disease.
a | Hepatobiliary lesions result from an architectural defect in the developing biliary tree. 
The normal ramifications of the portal venous system and the lattice-like network of 
associated biliary ducts (left) are disrupted owing to ductal plate malformation (DPM) 
(right), likely owing to a defect in terminal differentiation of cholangiocytes. b | The DPM 
results in marked cystic and fusiform dilatation of the intrahepatic biliary system (coronal 
T2-weighted image of the abdomen), nephromegaly with small cysts (arrowhead), cystic 
biliary disease (arrow) and marked splenomegaly (asterisk). c | The histopathological 
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manifestation of the DPM is congenital hepatic fibrosis (section stained with haematoxylin 
and eosin), which is characterized by extensive fibrosis of the portal area (asterisk), ectatic, 
tortuous bile ducts (arrows) and hypoplasia of the portal vein (arrowhead). Magnification is 
40×. Part a is reprinted, with permission, from Marchal G J, Desmet V J, Proesmans W C, et 
al. Caroli disease: high-frequency US and pathologic findings.
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Fig. 7 |. Diagnosis of autosomal dominant polycystic kidney disease using different imaging 
techniques.
a–b | Comparison of MRI (T2; part a) and CT (without contrast; part b) scans of a 35-year-
old woman with autosomal dominant polycystic kidney disease (ADPKD), showing 
widespread kidney cysts and a few liver cysts. c–e | T2 MRI images of patients with 
ADPKD who have a truncating mutation in PKD1 (part c; 41-year-old man), a non-
truncating mutation in PKD1 (part d, 40-year-old man) or a splicing mutation in PKD2 (part 
e; 41-year-old man). Patients with truncating mutations in PKD1 typically have more cysts, 
whereas patients with non-truncating mutations in PKD1 have an intermediate number of 
cysts and patients with splicing mutations in PKD2 have the fewest cysts.
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Fig. 8 |. Diagnosis of autosomal recessive polycystic kidney disease using MRI.
MRI can be used to detect renal and extrarenal manifestations of autosomal recessive 
polycystic kidney disease (ARPKD). In this coronal, T2-weighted MRI scan of a 32-week-
old fetus, the kidneys (arrow) are massively enlarged and are abnormally bright with 
innumerable tiny cysts, most of which cannot be individually resolved. Cystic biliary disease 
(arrowhead) and extremely low lung volumes (asterisk) in patients with ARPKD are due to 
oligohydramnios (deficiency of amniotic fluid).
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Table 2 |
Ultrasonography criteria for an ADPKD diagnosis in at-risk individuals
Age Genotype
PKD1 mutation PKD2 mutation Unknown ADPKD
genotype
15–30 years
• ≥3 cystsa
• PPV = 100%
• SEN = 94.3%
• ≥3 cystsa
• PPV = 100%
• SEN = 69.5%
• ≥3 cystsa
• PPV = 100%
• SEN = 81.7%
30–39 years
• ≥3 cystsa
• PPV = 100%
• SEN = 96.6%
• ≥3 cystsa
• PPV=100%
• SEN = 94.9%
• ≥3 cystsa
• PPV=100%
• SEN = 95.5%
40–59 years • ≥2 cysts in each kidney
• PPV = 100%
• SEN = 92.6%
• ≥2 cysts in each kidney
• PPV = 100%
• SEN = 88.8%
• ≥2 cysts in each kidney
• PPV = 100%
• SEN = 90%
Compiled with data from Ref.161. ADPKD, autosomal dominant polycystic kidney disease; PPV, positive predictive value; SEN, sensitivity.
aUnilateral or bilateral. All values are mean estimates.
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